Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; FEN, Fenofibrate; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	FEN	OCA	SEL	UDCA
Anaesthetics & Muscle Relaxants						
Bupivacaine	◆	◆	◆	◆	◆	◆
Cisatracurium	◆	◆	◆	◆	◆	◆
Desflurane	◆	◆	◆	◆	◆	◆
Dexmedetomidine	◆	△	◆	◆	◆	◆
Ephedrine	◆	◆	◆	◆	◆	◆
Etidocaine	◆	◆	◆	◆	◆	◆
Halothane	◆	◆	◆	◆	◆	◆
Isoflurane	◆	◆	◆	◆	◆	◆
Ketamine	◆	◆	◆	◆	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆	◆
Propofol	◆	◆	◆	◆	◆	◆
Remifentanil	◆	◆	◆	◆	◆	◆
Rocuronium	◆	◆	◆	◆	◆	◆
Sevoflurane	◆	◆	◆	◆	◆	◆
Tetracaine	◆	◆	◆	◆	◆	◆
Thiopental	◆	◆	◆	◆	◆	◆
Tizanidine	◆	◆	◆	■	◆	△
Analgesics						
Aceclofenac	◆	◆	◆	◆	◆	◆
Alfentanil	◆	◆	◆	◆	◆	◆
Aspirin	◆	◆	◆	◆	◆	◆
Buprenorphine	◆	△	◆	◆	◆	◆
Celecoxib	◆	◆	△	◆	◆	◆
Codeine	◆	◆	◆	◆	◆	△
Dexketoprofen	◆	◆	◆	◆	◆	◆
Dextropropoxyphene	◆	◆	◆	◆	◆	△
Diamorphine	◆	△	◆	◆	◆	△
Diclofenac	◆	◆	■	◆	△	◆
Diflunisal	◆	◆	◆	◆	◆	◆
Dihydrocodeine	◆	△	◆	◆	◆	△
Etodolac	◆	◆	◆	◆	◆	△
Etoricoxib	◆	◆	◆	△	◆	◆
Fentanyl (Prescribed)	◆	◆	◆	◆	◆	◆
Flurbiprofen	◆	△	◆	◆	◆	◆
Hydrocodone	◆	◆	◆	◆	◆	△
Hydromorphone	◆	△	◆	◆	◆	△
Ibuprofen	◆	△	◆	◆	◆	◆
Indometacin	◆	△	◆	△	◆	◆
Ketoprofen	◆	△	◆	◆	◆	◆
Mefenamic acid	◆	△	◆	◆	◆	◆
Meloxicam	◆	◆	△	△	◆	◆
Metamizole (Dipyrone)	◆	◆	◆	◆	◆	◆
Methadone	◆	◆	◆	■	◆	△
Morphine	◆	△	◆	◆	◆	◆
Naproxen	◆	△	◆	◆	△	◆
Nefopam	◆	◆	◆	◆	◆	◆
Oxycodone	◆	◆	◆	◆	◆	△
Paracetamol	◆	◆	◆	◆	◆	◆
Pethidine (Meperidine)	◆	◆	◆	◆	◆	△
Piroxicam	◆	◆	■	◆	◆	◆
Tapentadol	◆	◆	◆	◆	◆	△
Tramadol	◆	◆	◆	◆	◆	△
Anthelmintics						
Albendazole	◆	◆	◆	◆	◆	◆
Ivermectin	◆	◆	◆	◆	◆	◆
Niclosamide	◆	◆	◆	◆	◆	◆
Oxamniquine	◆	◆	◆	◆	◆	◆
Praziquantel	◆	◆	◆	△	◆	◆
Pyrantel	◆	◆	◆	◆	◆	◆
Antiarrhythmics						
Amiodarone	◆	◆	◆	△	■	△
Bepridil	◆	◆	◆	◆	◆	△
Digoxin	◆	◆	◆	◆	◆	◆
Disopyramide	◆	◆	◆	◆	◆	◆
Dofetilide	◆	◆	◆	◆	◆	△
Dronedarone	◆	◆	◆	△	◆	△
Flecainide	◆	◆	◆	◆	◆	△
Lidocaine (Lignocaine)	◆	◆	◆	◆	◆	◆
Mexiletine	◆	◆	◆	■	◆	△
Propafenone	◆	◆	◆	■	◆	△
Quinidine	◆	◆	◆	◆	◆	△
Vernakalant	◆	◆	◆	◆	◆	◆
Antibacterials						
Amikacin	◆	◆	◆	◆	◆	◆
Amoxicillin	◆	◆	◆	◆	◆	◆
Ampicillin	◆	◆	◆	◆	◆	◆
Azithromycin	◆	◆	◆	◆	◆	◆
Aztreonam	◆	◆	◆	◆	◆	◆
Bedaquiline	◆	◆	◆	◆	◆	◆
Benzylpenicillin	◆	◆	◆	◆	◆	◆
Bezlotoxumab	◆	◆	◆	◆	◆	◆
Capreomycin	◆	◆	◆	◆	◆	◆
Cefaclor	◆	◆	◆	◆	◆	◆
Cefadroxil	◆	◆	◆	◆	◆	◆
Cefalexin	◆	◆	◆	◆	◆	◆
Cefazolin	◆	◆	◆	◆	◆	◆
Cefixime	◆	◆	◆	◆	◆	◆

	BZF	ELA	FEN	OCA	SEL	UDCA
Antibacterials (continued)						
Cefotaxime	◆	◆	◆	◆	◆	◆
Cefradine	◆	◆	◆	◆	◆	◆
Ceftaroline	◆	◆	◆	◆	◆	◆
Ceftazidime	◆	◆	◆	◆	◆	◆
Ceftriaxone	◆	◆	◆	◆	◆	◆
Cefuroxime	◆	◆	◆	◆	◆	◆
Chloramphenicol	◆	△	◆	◆	◆	◆
Ciprofloxacin	◆	◆	◆	◆	◆	■
Clarithromycin	◆	◆	◆	◆	◆	◆
Clavulanic acid	◆	◆	◆	◆	◆	◆
Clindamycin	◆	◆	◆	◆	◆	△
Clofazimine	◆	◆	◆	◆	◆	◆
Cloxacillin	◆	◆	◆	◆	◆	◆
Cycloserine	◆	◆	◆	◆	◆	◆
Dapsone	◆	◆	◆	◆	◆	■
Daptomycin	■	◆	■	◆	◆	◆
Delamanid	◆	◆	◆	◆	◆	◆
Ertapenem	◆	◆	◆	◆	◆	◆
Erythromycin	■	◆	■	■	◆	◆
Ethambutol	◆	◆	◆	◆	◆	◆
Flucloxacillin	◆	◆	◆	◆	◆	◆
Fosfomycin	◆	◆	◆	◆	◆	◆
Gatifloxacin (topical)	◆	◆	◆	◆	◆	◆
Gentamicin	◆	◆	◆	◆	◆	◆
Imipenem	◆	◆	◆	◆	◆	◆
Isoniazid	◆	◆	◆	△	◆	◆
Levofloxacin	◆	◆	◆	◆	◆	◆
Linezolid	●	◆	◆	◆	◆	△
Lymecycline	◆	◆	◆	◆	◆	◆
Meropenem	◆	◆	◆	◆	◆	◆
Methenamine	◆	◆	◆	◆	◆	◆
Metronidazole	◆	◆	◆	◆	◆	◆
Minocycline	◆	◆	◆	◆	◆	◆
Moxifloxacin	◆	◆	◆	◆	◆	◆
Nitrofurantoin	◆	◆	◆	◆	◆	◆
Norfloxacin	◆	◆	◆	◆	◆	◆
Ofloxacin	◆	◆	◆	◆	◆	◆
Penicillin V	◆	◆	◆	◆	◆	◆
Piperacillin	◆	◆	◆	◆	◆	◆
Pivmecillinam	◆	◆	◆	◆	◆	◆
Pretomanid	◆	◆	◆	◆	■	△
Pyrazinamide	◆	◆	◆	◆	◆	◆
Rifabutin	◆	◆	◆	△	■	△
Rifampicin	◆	■	◆	△	■	△
Rifapentine	◆	■	◆	■	■	△
Rifaximin	◆	◆	◆	◆	◆	◆
Spectinomycin	◆	◆	◆	◆	◆	◆
Streptomycin	◆	◆	◆	◆	◆	◆
Sulfadiazine	◆	◆	◆	◆	◆	◆
Tazobactam	◆	◆	◆	◆	◆	◆
Telithromycin	◆	◆	◆	■	◆	◆
Temocillin	◆	◆	◆	◆	◆	◆
Tetracyclines	◆	◆	◆	◆	◆	◆
Ticarcillin	◆	◆	◆	◆	◆	◆
Tobramycin	◆	◆	◆	◆	◆	◆
Trimethoprim/Sulfamethoxazole	◆	◆	◆	◆	◆	◆
Troleandomycin	◆	◆	◆	◆	◆	◆
Vancomycin	◆	◆	◆	◆	◆	◆
Anticoagulant, Antiplatelet & Fibrinolytic						
Abciximab	◆	◆	◆	◆	◆	◆
Acenocoumarol	■	◆	■	△	◆	△
Anagrelide	◆	◆	◆	△	◆	△
Apixaban	◆	◆	◆	◆	◆	△
Caplacizumab	◆	◆	◆	◆	◆	◆
Clopidogrel	◆	△	△	△	◆	◆
Dabigatran	◆	◆	◆	◆	■	△
Dalteparin	◆	◆	◆	◆	◆	◆
Danaparoid	◆	◆	◆	◆	◆	◆
Dipyridamole	◆	◆	◆	■	◆	◆
Edoxaban	◆	◆	◆	◆	◆	△
Eltrombopag	◆	◆	◆	◆	■	◆
Enoxaparin	◆	◆	◆	◆	◆	◆
Fluindione	◆	◆	●	△	◆	△
Fondaparinux	◆	◆	◆	◆	◆	◆
Heparin	◆	◆	◆	◆	◆	◆
Natalizumab	◆	◆	◆	◆	◆	◆
Phenprocoumon	■	◆	■	◆	◆	△
Prasugrel	◆	◆	◆	◆	◆	◆
Rivaroxaban	◆	◆	◆	◆	◆	△
Streptokinase	◆	◆	◆	◆	◆	◆
Ticagrelor	◆	◆	◆	◆	◆	◆
Ticlopidine	◆	◆	△	◆	◆	◆
Tinzaparin	◆	◆	◆	◆	◆	◆
Warfarin	■	◆	■	■	◆	△

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; FEN, Fenofibrate; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	FEN	OCA	SEL	UDCA
Anticonvulsants						
Brivaracetam	◆	◆	◆	◆	△	◆
Carbamazepine	◆	■	◆	◆	■	△
Clonazepam	◆	◆	◆	◆	◆	◆
Eslicarbazepine	◆	◆	◆	◆	■	◆
Ethosuximide	◆	◆	◆	◆	◆	◆
Gabapentin	◆	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	◆	◆
Lamotrigine	◆	△	◆	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆	◆
Oxcarbazepine	◆	◆	◆	◆	■	◆
Perampanel	◆	◆	◆	◆	◆	◆
Phenobarbital	◆	■	◆	◆	■	△
Phenytoin	◆	■	■	◆	■	△
Pregabalin	◆	◆	◆	◆	◆	◆
Primidone	◆	■	◆	◆	■	◆
Retigabine	◆	◆	◆	◆	◆	◆
Rufinamide	◆	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	◆	◆
Tiagabine	◆	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆	◆
Valproic acid	◆	△	■	◆	◆	◆
Vigabatrin	◆	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆	◆
Antidepressants						
Agomelatine	◆	◆	◆	△	◆	◆
Amitriptyline	◆	◆	△	◆	◆	△
Bupropion	◆	◆	◆	◆	◆	◆
Citalopram	◆	◆	◆	◆	◆	◆
Clomipramine	◆	◆	◆	◆	◆	△
Desipramine	◆	◆	◆	◆	◆	△
Desvenlafaxine	◆	◆	◆	◆	◆	◆
Dosulepin	◆	◆	◆	◆	◆	△
Doxepin	◆	◆	◆	◆	◆	△
Duloxetine	◆	◆	◆	◆	◆	◆
Escitalopram	◆	◆	■	◆	◆	◆
Fluoxetine	◆	◆	◆	◆	◆	◆
Fluvoxamine	◆	◆	◆	◆	■	◆
Imipramine	◆	◆	◆	◆	◆	△
Lithium	◆	◆	◆	◆	◆	◆
Maprotiline	◆	◆	◆	◆	◆	△
Mianserin	◆	◆	◆	◆	◆	◆
Milnacipran	◆	◆	◆	◆	◆	◆
Mirtazapine	◆	◆	◆	◆	◆	△
Moclobemide	△	◆	◆	◆	◆	◆
Nefazodone	◆	◆	◆	■	◆	◆
Nortriptyline	◆	◆	◆	◆	◆	△
Opipramol	◆	◆	◆	◆	◆	◆
Paroxetine	◆	◆	◆	◆	◆	◆
Phenelzine	●	●	●	●	●	●
Reboxetine	◆	◆	◆	◆	◆	◆
Sertraline	◆	◆	◆	◆	◆	◆
Tianeptine	◆	◆	◆	◆	◆	◆
Trazodone	◆	◆	◆	◆	◆	◆
Trimipramine	◆	◆	◆	◆	◆	△
Venlafaxine	◆	◆	◆	◆	◆	◆
Vortioxetine	◆	◆	◆	◆	◆	◆
Antidiabetics						
Acarbose	■	◆	■	◆	◆	◆
Albiglutide	■	◆	■	◆	◆	◆
Alogliptin	■	◆	■	◆	◆	◆
Canagliflozin	■	◆	■	◆	◆	◆
Dapagliflozin	■	◆	■	◆	◆	◆
Dulaglutide	■	◆	■	◆	◆	◆
Empagliflozin	■	△	■	◆	◆	◆
Exenatide	■	◆	■	◆	◆	◆
Glibenclamide (Glyburide)	■	◆	■	■	◆	△
Gliclazide	■	◆	■	◆	◆	◆
Glimepiride	■	◆	■	■	◆	△
Glipizide	■	◆	■	◆	◆	△
Insulin	■	◆	■	◆	◆	◆
Linagliptin	■	◆	■	◆	◆	◆
Liraglutide	■	◆	■	◆	◆	◆
Lixisenatide	■	◆	■	◆	◆	◆
Metformin	■	◆	■	◆	◆	◆
Nateglinide	■	◆	■	◆	◆	◆
Pioglitazone	■	◆	■	△	◆	◆
Repaglinide	■	◆	■	△	◆	◆
Rosiglitazone	■	◆	■	■	◆	◆
Saxagliptin	■	◆	■	◆	◆	◆
Semaglutide	■	◆	■	◆	◆	◆
Sitagliptin	■	◆	■	◆	◆	◆
Tirzepatide	■	◆	■	◆	◆	◆
Tolbutamide	■	◆	■	◆	◆	△
Vildagliptin	■	◆	■	◆	◆	◆

	BZF	ELA	FEN	OCA	SEL	UDCA
Antifungals						
Amphotericin B	◆	◆	◆	◆	◆	◆
Anidulafungin	◆	◆	◆	◆	◆	◆
Caspofungin	◆	◆	◆	◆	◆	◆
Clotrimazole (pessary)	◆	◆	◆	◆	◆	◆
Clotrimazole (topical)	◆	◆	◆	◆	◆	◆
Fluconazole	◆	◆	◆	◆	■	◆
Flucytosine	◆	◆	◆	◆	◆	◆
Griseofulvin	◆	◆	◆	◆	◆	◆
Isavuconazole	◆	◆	◆	◆	△	◆
Itraconazole	◆	◆	◆	■	◆	△
Ketoconazole	◆	◆	◆	■	◆	△
Miconazole	◆	◆	◆	◆	■	◆
Nystatin	◆	◆	◆	◆	◆	◆
Posaconazole	◆	◆	◆	■	◆	△
Terbinafine	◆	◆	■	◆	◆	◆
Voriconazole	◆	◆	■	◆	■	△
Antihaemorrhagics						
Avatrombopag	◆	◆	■	◆	●	△
Eltrombopag	◆	◆	◆	◆	◆	◆
Tranexamic acid	◆	◆	◆	◆	◆	◆
Antihistamines						
Astemizole	◆	◆	◆	△	◆	△
Bilastine	◆	◆	◆	◆	◆	◆
Cetirizine	◆	◆	◆	◆	◆	◆
Chlorphenamine	◆	◆	◆	◆	◆	△
Clemastine	◆	◆	◆	◆	◆	◆
Desloratadine	◆	◆	◆	◆	◆	◆
Diphenhydramine	◆	◆	◆	◆	◆	◆
Doxylamine	◆	◆	◆	■	◆	◆
Ebastine	◆	◆	◆	◆	◆	◆
Fexofenadine	◆	◆	◆	◆	◆	◆
Hydroxyzine	◆	◆	◆	■	◆	◆
Levocetirizine	◆	◆	◆	◆	◆	◆
Loratadine	◆	◆	◆	■	◆	◆
Promethazine	◆	◆	◆	◆	◆	◆
Terfenadine	◆	◆	◆	◆	◆	△
Antimigraine Agents						
Almotriptan	◆	◆	◆	◆	◆	◆
Dihydroergotamine	◆	◆	◆	◆	◆	◆
Eletriptan	◆	◆	◆	◆	◆	◆
Eptinezumab	◆	◆	◆	◆	◆	◆
Ergotamine	◆	◆	◆	◆	◆	△
Fremanezumab	◆	◆	◆	◆	◆	◆
Frovatriptan	◆	◆	◆	◆	◆	◆
Galcanezumab	◆	◆	◆	◆	◆	◆
Methylergonovine	◆	◆	◆	◆	◆	△
Naratriptan	◆	◆	◆	◆	◆	◆
Pizotifen	◆	◆	◆	◆	◆	◆
Rizatriptan	◆	◆	◆	◆	◆	◆
Sumatriptan	◆	◆	◆	◆	◆	◆
Zolmitriptan	◆	◆	◆	■	◆	◆
Antiprotozoals						
Amodiaquine	◆	◆	◆	◆	◆	△
Artemether	◆	◆	◆	◆	◆	◆
Artesunate	◆	△	◆	◆	◆	◆
Atovaquone	◆	◆	◆	◆	◆	△
Chloroquine	■	◆	■	◆	◆	△
Dihydroartemisinin	◆	△	◆	◆	◆	◆
Doxycycline	◆	◆	◆	◆	◆	◆
Halofantrine	◆	◆	◆	◆	◆	△
Hydroxychloroquine	■	◆	■	◆	◆	◆
Lumefantrine	◆	◆	◆	◆	◆	◆
Mefloquine	◆	◆	◆	◆	◆	◆
Nitazoxanide	◆	◆	◆	◆	◆	◆
Pentamidine	◆	◆	◆	◆	◆	◆
Piperaquine	◆	◆	◆	◆	◆	△
Primaquine	◆	◆	◆	△	◆	◆
Proguanil	◆	◆	◆	◆	◆	◆
Pyrimethamine	◆	◆	◆	◆	◆	△
Quinine	◆	◆	◆	◆	◆	△
Sodium stibogluconate	◆	◆	◆	◆	◆	◆
Sulfadoxine	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; FEN, Fenofibrate; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	FEN	OCA	SEL	UDCA
Antipsychotics/Neuroleptics						
Amisulpride	◆	◆	◆	◆	◆	◆
Aripiprazole	◆	◆	◆	◆	◆	◆
Asenapine	◆	◆	◆	△	◆	◆
Brexpiprazole	◆	◆	◆	◆	◆	△
Cariprazine	◆	◆	◆	◆	◆	△
Chlorpromazine	◆	◆	◆	◆	◆	◆
Chlorprothixene	◆	◆	◆	◆	◆	△
Clozapine	◆	◆	◆	■	◆	◆
Flupentixol	◆	◆	◆	◆	◆	△
Fluphenazine	◆	◆	◆	△	◆	◆
Haloperidol	◆	△	◆	◆	◆	△
Iloperidone	◆	◆	◆	△	◆	△
Levomepromazine	◆	◆	◆	◆	◆	◆
Loxapine	◆	◆	◆	◆	◆	◆
Lurasidone	◆	◆	◆	◆	◆	◆
Melperone	◆	◆	◆	◆	◆	◆
Olanzapine	◆	◆	◆	■	◆	◆
Paliperidone	◆	◆	◆	◆	◆	△
Perazine	◆	◆	◆	◆	◆	◆
Periciazine	◆	◆	◆	◆	◆	◆
Perphenazine	◆	◆	◆	◆	◆	◆
Pimozide	◆	◆	◆	◆	◆	△
Pipotiazine	◆	◆	◆	◆	◆	◆
Prochlorperazine	◆	◆	◆	◆	◆	◆
Promazine	◆	◆	◆	◆	◆	△
Quetiapine	◆	◆	◆	◆	◆	◆
Risperidone	◆	◆	◆	◆	◆	◆
Sulpiride	◆	◆	◆	◆	◆	◆
Tiapride	◆	◆	◆	◆	◆	◆
Trifluoperazine	◆	◆	◆	◆	◆	◆
Ziprasidone	◆	◆	◆	◆	◆	◆
Zuclopentixol	◆	◆	◆	◆	◆	△
Antivirals						
Aciclovir	◆	◆	◆	◆	◆	◆
Amantadine	◆	◆	◆	◆	◆	◆
Ansuvimab	◆	◆	◆	◆	◆	◆
Brincidofovir	◆	◆	◆	◆	■	◆
Brivudine	◆	◆	◆	◆	◆	◆
Cidofovir	◆	◆	◆	◆	◆	◆
Favipiravir	◆	◆	◆	◆	△	◆
Foscarnet	◆	◆	◆	◆	◆	◆
Letermovir	◆	◆	◆	◆	■	◆
Molnupiravir	◆	◆	◆	◆	◆	◆
Nirmatrelvir/ritonavir	◆	◆	◆	◆	■	◆
Oseltamivir	◆	◆	◆	◆	◆	◆
Remdesivir	◆	◆	◆	◆	◆	◆
Rimantadine	◆	◆	◆	◆	◆	◆
Sotrovimab	◆	◆	◆	◆	◆	◆
Tecovirimat	◆	△	◆	◆	◆	◆
Tixagevimab/cilgavimab	◆	◆	◆	◆	◆	◆
Valaciclovir	◆	◆	◆	◆	◆	◆
Zanamivir	◆	◆	◆	◆	◆	◆
Anxiolytics/Hypnotics/Sedatives						
Alprazolam	◆	◆	◆	◆	◆	◆
Amobarbital	◆	■	◆	◆	◆	△
Bromazepam	◆	◆	◆	◆	◆	◆
Bromperidol	◆	◆	◆	◆	◆	◆
Buspirone	◆	◆	◆	◆	◆	◆
Chlordiazepoxide	◆	◆	△	◆	◆	◆
Clobazam	◆	◆	◆	◆	◆	◆
Clorazepate	◆	◆	◆	◆	◆	◆
Clotiapine	◆	◆	△	◆	◆	◆
Daridorexant	◆	■	◆	◆	△	△
Diazepam	◆	◆	◆	◆	◆	◆
Estazolam	◆	◆	◆	◆	◆	◆
Flurazepam	◆	◆	◆	◆	◆	◆
Lemborexant	◆	◆	◆	◆	◆	◆
Lorazepam	◆	◆	◆	◆	◆	◆
Lormetazepam	◆	◆	◆	◆	◆	◆
Midazolam (oral)	◆	◆	◆	△	◆	◆

	BZF	ELA	FEN	OCA	SEL	UDCA
Anxiolytics/Hypnotics/Sedatives continued						
Midazolam (parenteral)	◆	◆	◆	△	◆	◆
Nitrazepam	◆	◆	◆	◆	◆	◆
Oxazepam	◆	◆	◆	◆	◆	◆
Quazepam	◆	◆	◆	◆	◆	◆
Temazepam	◆	◆	◆	◆	◆	◆
Triazolam	◆	◆	◆	◆	◆	◆
Zaleplon	◆	◆	◆	◆	◆	◆
Zolpidem	◆	◆	◆	◆	◆	◆
Zopiclone	◆	◆	◆	◆	◆	◆
Beta Blockers						
Atenolol	◆	◆	◆	◆	◆	◆
Bisoprolol	◆	◆	◆	◆	◆	◆
Carvedilol	◆	△	◆	◆	◆	△
Celiprolol	◆	◆	◆	◆	◆	△
Labetalol	◆	△	◆	◆	◆	△
Metoprolol	◆	◆	◆	◆	◆	◆
Nebivolol	◆	◆	◆	◆	◆	△
Oxprenolol	◆	◆	◆	◆	◆	◆
Pindolol	◆	◆	◆	◆	◆	◆
Propranolol	◆	◆	◆	◆	◆	△
Sotalol	◆	◆	◆	◆	◆	◆
Timolol	◆	◆	◆	◆	◆	△
Bisphosphonates						
Alendronic acid	◆	◆	◆	◆	◆	◆
Clodronate	◆	◆	◆	◆	◆	◆
Ibandronic acid	◆	◆	◆	◆	◆	◆
Pamidronate	◆	◆	◆	◆	◆	◆
Risedronate	◆	◆	◆	◆	◆	◆
Zoledronic acid	◆	◆	◆	◆	◆	◆
Bronchodilators						
Aclidinium bromide	◆	◆	◆	◆	◆	◆
Aminophylline	◆	◆	◆	◆	◆	◆
Formoterol	◆	◆	◆	◆	◆	◆
Indacaterol	◆	◆	◆	◆	◆	◆
Ipratropium bromide	◆	◆	◆	◆	◆	◆
Montelukast	◆	◆	◆	◆	◆	◆
Omalizumab	◆	◆	◆	◆	◆	◆
Reslizumab	◆	◆	◆	◆	◆	◆
Salbutamol	◆	◆	◆	◆	◆	◆
Salmeterol	◆	◆	◆	◆	◆	◆
Theophylline	◆	◆	◆	■	◆	◆
Tiotropium	◆	◆	◆	◆	◆	◆
Umeclidinium bromide	◆	◆	◆	◆	◆	◆
Vilanterol	◆	◆	◆	◆	◆	◆
Calcium Channel Blockers						
Amlodipine	◆	◆	◆	◆	◆	△
Diltiazem	◆	◆	◆	◆	◆	△
Felodipine	◆	◆	◆	△	◆	△
Nicardipine	◆	◆	◆	■	■	△
Nifedipine	◆	◆	◆	△	◆	△
Nisoldipine	◆	◆	◆	△	◆	△
Nitrendipine	◆	◆	◆	△	◆	■
Verapamil	◆	◆	◆	◆	◆	△

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; FEN, Fenofibrate; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	FEN	OCA	SEL	UDCA
Cancer Therapies						
Abiraterone	◆	◆	◆	◆	◆	◆
Acalabrutinib	◆	◆	◆	◆	◆	△
Afatinib	◆	◆	◆	◆	◆	◆
Alectinib	■	◆	■	◆	■	△
Alpelisib	◆	◆	◆	◆	◆	◆
Amivantamab	◆	◆	◆	◆	◆	◆
Anastrozole	◆	◆	◆	◆	◆	◆
Apalutamide	◆	■	◆	◆	■	△
Asciminib	◆	△	◆	◆	■	◆
Asparaginase	◆	◆	◆	◆	◆	◆
Atezolizumab	■	◆	■	◆	◆	◆
Avapritinib	■	◆	■	△	■	◆
Avelumab	◆	◆	◆	◆	◆	◆
Axitinib	◆	◆	◆	◆	◆	◆
Azacitidine	■	◆	■	◆	◆	◆
Belantamab mafodotin	◆	◆	◆	◆	◆	◆
Bendamustine	◆	◆	◆	◆	◆	◆
Bevacizumab	◆	◆	◆	◆	◆	◆
Bexarotene	■	◆	■	◆	■	△
Bicalutamide	◆	◆	◆	◆	◆	◆
Binimetinib	■	◆	■	◆	△	△
Blinatumomab	◆	◆	◆	◆	◆	◆
Bortezomib	◆	◆	◆	◆	◆	◆
Bosutinib	◆	◆	◆	◆	◆	◆
Brentuximab vedotin	◆	◆	◆	◆	◆	◆
Brigatinib	■	■	■	◆	■	△
Cabozantinib	◆	◆	◆	◆	◆	△
Capecitabine	◆	◆	◆	◆	■	◆
Capmatinib	◆	◆	◆	◆	■	△
Carboplatin	◆	◆	◆	◆	◆	◆
Carfilzomib	◆	◆	◆	◆	◆	◆
Cedazuridine	◆	◆	◆	◆	◆	◆
Ceritinib	◆	◆	◆	◆	■	△
Cetuximab	◆	◆	◆	◆	◆	◆
Chlorambucil	◆	◆	◆	◆	◆	△
Cisplatin	◆	◆	◆	◆	◆	◆
Cladribine (IV)	◆	◆	◆	◆	◆	◆
Cobimetinib	■	△	■	◆	◆	△
Crizotinib	◆	◆	◆	◆	◆	◆
Cyclophosphamide	◆	◆	◆	◆	◆	◆
Cytarabine	■	◆	■	◆	◆	◆
Dabrafenib	■	■	■	◆	■	△
Daratumumab	◆	◆	◆	◆	◆	◆
Dasatinib	◆	◆	◆	■	◆	◆
Decitabine	◆	◆	◆	◆	◆	◆
Docetaxel	■	◆	■	◆	◆	◆
Doxorubicin	◆	◆	◆	◆	◆	◆
Durvalumab	◆	◆	◆	◆	◆	◆
Duvelisib	■	◆	■	◆	■	△
Elotuzumab	◆	◆	◆	◆	◆	◆
Elranatamab	◆	◆	◆	◆	◆	◆
Encorafenib	■	◆	■	◆	■	△
Enfortumab vedotin	◆	◆	◆	◆	◆	◆
Enzalutamide	◆	■	◆	◆	■	△
Epcoritamab	◆	◆	◆	◆	◆	◆
Epirubicin	◆	△	◆	◆	◆	◆
Erlotinib	◆	◆	◆	◆	◆	△
Estramustine	◆	◆	◆	◆	◆	△
Etoposide	◆	◆	◆	◆	◆	◆
Everolimus	◆	◆	◆	■	◆	△
Exemestane	◆	◆	◆	△	◆	◆
Fludarabine	◆	◆	◆	◆	◆	◆
Fluorouracil (5-FU)	◆	◆	◆	◆	■	◆
Garadacimab	◆	◆	◆	◆	◆	◆
Gefitinib	◆	◆	◆	■	■	◆
Gemcitabine	◆	◆	◆	◆	◆	◆
Gemtuzumab ozogamicin	◆	◆	◆	◆	◆	◆
Glofitamab	◆	◆	◆	◆	◆	◆
Hydroxyurea (Hydroxycarbamide)	◆	◆	◆	◆	◆	◆
Ibrutinib	◆	◆	◆	◆	◆	△

	BZF	ELA	FEN	OCA	SEL	UDCA
Cancer Therapies continued						
Idarubicin	◆	◆	◆	◆	◆	△
Idelalisib	◆	◆	◆	◆	◆	△
Imatinib	◆	◆	◆	△	■	◆
Inotuzumab ozogamicin	◆	◆	◆	◆	◆	◆
Ipilimumab	◆	◆	◆	◆	◆	◆
Irinotecan	◆	◆	◆	◆	◆	◆
Isatuximab	◆	◆	◆	◆	◆	◆
Ixazomib	◆	◆	◆	◆	◆	◆
Lapatinib	◆	■	◆	■	■	◆
Letrozole	◆	◆	◆	◆	◆	◆
Loncastuximab tesirine	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (oncology)	◆	◆	◆	■	◆	■
Mercaptopurine	◆	◆	◆	◆	◆	◆
Mesna	◆	◆	◆	◆	◆	◆
Methotrexate	◆	◆	◆	◆	◆	◆
Mitoxantrone	◆	■	■	◆	◆	◆
Mogamulizumab	◆	◆	◆	◆	◆	◆
Nilotinib	◆	◆	◆	◆	■	◆
Niraparib	◆	◆	◆	◆	◆	◆
Nivolumab	◆	◆	◆	◆	◆	◆
Obinutuzumab	◆	◆	◆	◆	◆	◆
Ofatumumab	◆	◆	◆	◆	◆	◆
Olaparib	◆	◆	◆	◆	△	◆
Olaratumab	◆	◆	◆	◆	◆	◆
Osimertinib	◆	◆	◆	◆	△	△
Oxaliplatin	◆	◆	◆	◆	◆	◆
Paclitaxel	◆	◆	◆	△	◆	◆
Panitumumab	◆	◆	◆	◆	◆	◆
Panobinostat	◆	◆	◆	◆	◆	△
Pertuzumab	◆	◆	◆	◆	◆	◆
Polatuzumab vedotin	◆	◆	◆	◆	◆	◆
Pomalidomide	◆	◆	◆	◆	◆	◆
Ponatinib	◆	◆	◆	◆	◆	◆
Ramucirumab	◆	◆	◆	◆	◆	◆
Retifanlimab	◆	◆	◆	◆	◆	◆
Ribociclib	◆	◆	◆	△	■	◆
Rituximab	◆	◆	◆	◆	◆	◆
Rucaparib	◆	◆	◆	△	■	◆
Ruxolitinib	◆	◆	◆	◆	■	◆
Sacituzumab govitecan	◆	◆	◆	◆	◆	◆
Selpercatinib	◆	◆	◆	◆	△	◆
Sotorasib	◆	◆	◆	◆	△	△
Sunitinib	◆	■	◆	△	■	△
Talazoparib	◆	◆	◆	◆	◆	◆
Tamoxifen	◆	◆	◆	◆	◆	◆
Tegafur/Gimeracil/Oteracil	◆	◆	●	◆	■	◆
Temsirolimus	◆	◆	◆	■	◆	◆
Tepotinib	◆	◆	◆	◆	△	◆
Thioguanine	◆	◆	◆	◆	◆	◆
Tisotumab vedotin	◆	◆	◆	◆	◆	◆
Tivozanib	◆	◆	◆	◆	△	◆
Topotecan (IV)	◆	◆	◆	◆	△	◆
Topotecan (oral)	◆	■	◆	◆	△	◆
Trametinib	■	◆	■	◆	△	◆
Trastuzumab	◆	◆	◆	◆	◆	◆
Trastuzumab deruxtecan	◆	◆	◆	◆	◆	◆
Trastuzumab emtansine	◆	◆	◆	◆	◆	◆
Tremelimumab	◆	◆	◆	◆	◆	◆
Trifluridine/tipiracil	◆	◆	◆	◆	◆	◆
Vemurafenib	◆	◆	◆	◆	■	△
Venetoclax	◆	■	◆	◆	◆	◆
Vinblastine	◆	◆	◆	◆	◆	◆
Vincristine	◆	◆	◆	◆	◆	◆
Vinorelbine	◆	◆	◆	◆	◆	◆
Zolbetuximab	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; FEN, Fenofibrate; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	FEN	OCA	SEL	UDCA
Contraceptives and Hormone Replacements						
Conjugated estrogens (HRT)	◆	◆	◆	■	◆	◆
Desogestrel (POP)	◆	■	◆	◆	◆	◆
Desogestrel/ethinylestradiol (COC) (>20 µg)	◆	■	◆	■	◆	◆
Desogestrel/ethinylestradiol (COC) (≤20 µg)	◆	■	◆	■	◆	◆
Dienogest	◆	◆	◆	◆	◆	◆
Dienogest/estradiol valerate (COC)	◆	■	◆	◆	◆	◆
Drospirenone (POP)	◆	■	◆	■	◆	◆
Drospirenone/estradiol (HRT)	◆	◆	◆	■	◆	◆
Drospirenone/ethinylestradiol (COC) (>20 µg)	◆	■	◆	■	◆	◆
Drospirenone/ethinylestradiol (COC) (≤20 µg)	◆	■	◆	■	◆	◆
Dydrogesterone/estradiol (HRT)	◆	◆	◆	◆	◆	◆
Estradiol	◆	◆	◆	◆	◆	◆
Ethinylestradiol (>20 µg)	◆	■	◆	■	◆	◆
Ethinylestradiol (≤20 µg)	◆	■	◆	■	◆	◆
Etonogestrel (implant)	◆	■	◆	◆	◆	◆
Etonogestrel (vaginal ring)	◆	■	◆	◆	◆	◆
Gestodene/ethinylestradiol (COC) (>20 µg)	◆	■	◆	■	◆	◆
Gestodene/ethinylestradiol (COC) (≤20 µg)	◆	■	◆	■	◆	◆
Levonorgestrel (Emergency Contraception)	◆	■	◆	◆	◆	◆
Levonorgestrel (HRT)	◆	◆	◆	◆	◆	◆
Levonorgestrel (implant)	◆	■	◆	◆	◆	◆
Levonorgestrel (IUD)	◆	◆	◆	◆	◆	◆
Levonorgestrel (POP)	◆	■	◆	◆	◆	◆
Levonorgestrel/ethinyl-estradiol (COC) (>20 µg)	◆	■	◆	■	◆	◆
Levonorgestrel/ethinyl-estradiol (COC) (≤20 µg)	◆	■	◆	■	◆	◆
Medroxyprogesterone (depot)	◆	■	◆	■	◆	◆
Medroxyprogesterone (oral)	◆	◆	◆	■	◆	◆
Medroxyprogesterone/ conjugated estrogens (HRT)	◆	◆	◆	■	◆	◆
Medroxyprogesterone/ estradiol (HRT)	◆	◆	◆	■	◆	◆
Micronized progesterone (HRT)	◆	◆	◆	◆	◆	◆
Norelgestromin/ethinylestradiol (patch)	◆	■	◆	■	◆	◆
Norethisterone (Norethindrone) (depot injection)	◆	■	◆	△	◆	◆
Norethisterone (Norethindrone) (POP)	◆	■	◆	△	◆	◆
Norethisterone (Norethindrone)/estradiol (HRT)	◆	◆	◆	△	◆	◆
Norethisterone (Norethindrone) ethinylestradiol (COC)	◆	■	◆	■	◆	◆
Norethisterone (Norethindrone)/mestranol (COC)	◆	■	◆	■	◆	◆
Norgestimate/ethinylestradiol (COC)	◆	■	◆	■	◆	◆
Norgestrel/conjugated estrogens (HRT)	◆	◆	◆	■	◆	◆
Norgestrel/ethinylestradiol (COC)	◆	■	◆	■	◆	◆
Testosterone	◆	◆	◆	◆	◆	◆
Erectile Dysfunction Agents						
Sildenafil	◆	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	◆	◆
Vardenafil	◆	◆	◆	◆	◆	◆
Yohimbine	◆	◆	◆	◆	◆	◆

	BZF	ELA	FEN	OCA	SEL	UDCA
Gastrointestinal Agents						
Aluminium hydroxide	◆	◆	◆	◆	◆	■
Alverine citrate	◆	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	◆	◆	■
Aprepitant	◆	◆	◆	◆	◆	◆
Bisacodyl	◆	◆	◆	◆	◆	◆
Bismuth subsalicylate	◆	◆	◆	◆	◆	◆
Cimetidine	◆	◆	◆	◆	■	◆
Cisapride	◆	◆	◆	△	◆	△
Cyclizine	◆	◆	◆	◆	◆	◆
Dantron	◆	◆	◆	◆	◆	◆
Docusate sodium	◆	◆	◆	◆	◆	◆
Domperidone	◆	◆	◆	◆	◆	◆
Droperidol	◆	◆	◆	◆	◆	◆
Esomeprazole	◆	◆	◆	◆	◆	◆
Famotidine	◆	◆	◆	◆	◆	◆
Granisetron	◆	◆	◆	◆	◆	◆
Hyoscine (Scopolamine)	◆	◆	◆	◆	◆	◆
Hyoscine butylbromide	◆	◆	◆	◆	◆	◆
Hyoscine hydrobromide (Scopolamine hydrobromide)	◆	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	◆	◆
Lafutidine	◆	◆	◆	◆	◆	◆
Lansoprazole	◆	◆	◆	◆	◆	◆
Linaclotide	◆	◆	◆	◆	◆	◆
Loperamide	◆	◆	◆	◆	◆	◆
Lubiprostone	◆	◆	◆	◆	◆	◆
Macrogol	△	◆	△	△	◆	△
Mebeverine	◆	◆	◆	◆	◆	◆
Mesalazine	◆	◆	◆	◆	◆	◆
Methylcellulose	◆	◆	◆	◆	◆	◆
Metoclopramide	◆	◆	◆	◆	◆	◆
Naldemedine	◆	◆	◆	◆	◆	◆
Naloxegol	◆	◆	◆	◆	◆	◆
Nizatidine	◆	◆	◆	◆	◆	◆
Omeprazole	◆	◆	◆	◆	◆	◆
Ondansetron	◆	◆	◆	◆	◆	◆
Pantoprazole	◆	◆	◆	◆	◆	◆
Prucalopride	◆	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	◆	△	◆	◆
Ranitidine	◆	◆	◆	◆	◆	◆
Roxatidine	◆	◆	◆	◆	◆	◆
Senna	◆	◆	◆	◆	◆	◆
Simeticone	◆	◆	◆	◆	◆	◆
Sulfasalazine	◆	◆	◆	◆	◆	◆
Trimebutine	◆	◆	◆	◆	◆	◆
Vonoprazan	◆	◆	◆	◆	◆	◆
HCC Therapies						
Atezolizumab + bevacizumab	■	◆	■	◆	◆	◆
Lenvatinib	◆	■	◆	◆	◆	◆
Pembrolizumab	◆	◆	◆	◆	◆	◆
Regorafenib	◆	◆	◆	◆	■	◆
Sorafenib	◆	◆	◆	◆	■	◆
Hepatitis B Drugs						
Adefovir	◆	◆	◆	△	◆	◆
Entecavir	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆
Peginterferon alfa-2a	◆	◆	◆	◆	◆	◆
Peginterferon alfa-2b	◆	◆	◆	◆	◆	◆
Ribavirin	◆	◆	◆	◆	◆	◆
Telbivudine	■	■	■	◆	◆	◆
Tenofovir alafenamide	◆	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	◆	△	◆
Hepatitis C Drugs						
Daclatasvir	◆	◆	◆	◆	■	◆
Elbasvir/Grazoprevir	◆	◆	◆	◆	■	◆
Glecaprevir/Pibrentasvir	◆	◆	◆	◆	■	◆
Ledipasvir/Sofosbuvir	◆	◆	◆	◆	■	◆
OBV/PTV/r	◆	◆	◆	◆	■	◆
OBV/PTV/r + Dasabuvir	◆	◆	◆	◆	■	◆
Ravidasvir	◆	◆	◆	◆	■	◆
Ribavirin	◆	◆	◆	◆	◆	◆
Sofosbuvir (SOF)	◆	◆	◆	◆	◆	◆
SOF/Velpatasvir	◆	◆	◆	◆	■	◆
SOF/Velpatasvir/ Voxilaprevir	◆	◆	◆	◆	■	◆
Hepatitis D Entry Inhibitors						
Bulevirtide	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; FEN, Fenofibrate; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	FEN	OCA	SEL	UDCA
Herbals/Supplements/Vitamins						
Aloe vera	◆	◆	◆	◆	◆	◆
Ascorbic acid (Vitamin C)	◆	◆	◆	◆	◆	◆
Ashwagandha (Withania somnifera)	◆	◆	◆	◆	◆	◆
Black cohosh (A. racemosa)	◆	◆	◆	◆	◆	◆
Calcium carbonate	◆	◆	◆	◆	◆	◆
Cat's claw (U. tomentosa)	◆	◆	◆	◆	◆	◆
Choline alfoscerate	◆	◆	◆	◆	◆	◆
Colecalciferol (Vitamin D3)	◆	◆	◆	◆	◆	◆
Collagen	◆	◆	◆	◆	◆	◆
Cyanocobalamin (B12)	◆	◆	◆	◆	◆	◆
Diosmin	◆	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆	◆
Enteral feeds	◆	◆	◆	◆	◆	◆
Eucalyptus globulus	◆	◆	◆	◆	◆	◆
Ferrous sulphate	◆	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆	◆
Garlic	◆	◆	◆	◆	◆	◆
Ginger (Z. officinale)	◆	◆	◆	◆	◆	◆
Ginkgo biloba	◆	◆	◆	◆	◆	◆
Ginseng	◆	◆	◆	◆	◆	◆
Goldenseal (H. canadensis)	◆	◆	◆	◆	◆	◆
Grape seed extract	◆	◆	◆	◆	◆	◆
Grapefruit juice	◆	◆	◆	◆	◆	◆
Green tea (C. sinensis)	◆	◆	◆	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆	◆
Hydroxocobalamin (Vitamin B12)	◆	◆	◆	◆	◆	◆
Inula racemosa	◆	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆	◆
Kava kava (P. methysticum)	◆	◆	◆	◆	◆	◆
L-lysine	◆	◆	◆	◆	◆	◆
Menthol	◆	◆	◆	◆	◆	◆
Milk thistle	◆	◆	◆	■	◆	◆
Mucuna pruriens	◆	◆	◆	◆	◆	◆
Niacin (Vitamin B3)	■	◆	■	◆	◆	◆
Oral nutritional supplements	◆	◆	◆	◆	◆	◆
Oregano oil	◆	◆	◆	◆	◆	◆
Pyridoxine (Vitamin B6)	◆	◆	◆	◆	◆	◆
Retinol (Vitamin A)	◆	◆	◆	◆	◆	◆
Riboflavin (Vitamin B2)	◆	◆	◆	◆	◆	◆
Saw palmetto (*S. repens*)	◆	◆	◆	◆	◆	◆
St John's wort	◆	■	◆	◆	■	◆
Thiamine (Vitamin B1)	◆	◆	◆	◆	◆	◆
Turmeric (curcumin)	◆	◆	◆	◆	■	◆
Valerian	◆	◆	◆	◆	◆	◆
Vitamin E	◆	◆	◆	◆	◆	◆
Zinc	◆	◆	◆	◆	◆	◆

	BZF	ELA	FEN	OCA	SEL	UDCA
HIV Drugs						
Entry/Integrase Inhibitors						
Albuvirtide	◆	◆	◆	◆	◆	◆
Bictegravir/FTC/TAF	◆	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (LA)	◆	◆	◆	◆	◆	■
Dolutegravir	◆	◆	◆	◆	◆	◆
Dolutegravir/ABC/3TC	◆	◆	◆	◆	◆	◆
Dolutegravir/3TC	◆	◆	◆	◆	◆	◆
Dolutegravir/rilpivirine	◆	◆	◆	◆	◆	■
Elvitegravir/cobi /FTC/TAF	◆	◆	◆	◆	■	◆
Elvitegravir/cobi/FTC/TDF	◆	◆	◆	◆	■	◆
Enfuvirtide	◆	◆	◆	◆	◆	◆
Fostemsavir	◆	◆	◆	◆	■	◆
Ibalizumab-uiyk	◆	◆	◆	◆	◆	◆
Lenacapavir	◆	◆	◆	◆	◆	■
Maraviroc	◆	◆	◆	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆	◆
NNRTIs						
Dapivirine	◆	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	◆	◆
Doravirine/3TC/TDF	◆	◆	◆	◆	△	◆
Efavirenz	◆	■	◆	◆	■	△
Etravirine	◆	◆	◆	◆	■	◆
Nevirapine	◆	■	◆	◆	■	△
Rilpivirine	◆	◆	◆	◆	◆	■
Rilpivirine/FTC/TAF	◆	◆	◆	◆	◆	■
NRTIs						
Abacavir	◆	◆	◆	◆	◆	◆
Didanosine	◆	◆	◆	◆	◆	◆
Emtricitabine (FTC)	◆	◆	◆	◆	◆	◆
Emtricitabine + TAF	◆	◆	◆	◆	◆	◆
Emtricitabine + TDF	◆	◆	◆	◆	△	◆
Lamivudine	◆	◆	◆	◆	◆	◆
Stavudine	◆	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	◆	△	◆
Zidovudine	■	◆	■	◆	◆	◆
Protease Inhibitors						
Atazanavir + ritonavir	◆	◆	◆	■	■	◆
Atazanavir alone	◆	◆	◆	■	◆	◆
Atazanavir/cobicistat	◆	◆	◆	■	■	◆
Darunavir + ritonavir	◆	◆	◆	■	■	◆
Darunavir/cobicistat	◆	◆	◆	◆	■	◆
Darunavir/cobi/FTC/TAF	◆	◆	◆	◆	■	◆
Fosamprenavir	◆	◆	◆	■	■	◆
Indinavir	◆	◆	◆	■	■	△
Lopinavir	◆	◆	◆	■	■	△
Ritonavir	◆	◆	◆	■	■	◆
Tipranavir	◆	◆	◆	■	■	△

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.* *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; FEN, Fenofibrate; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	FEN	OCA	SEL	UDCA
Hypertension/Heart Failure Agents						
Acebutolol	◆	◆	◆	◆	◆	◆
Aliskiren	◆	◆	◆	◆	◆	◆
Ambrisentan	◆	◆	◆	◆	◆	◆
Amiloride	◆	◆	◆	◆	◆	◆
Azilsartan	◆	◆	◆	◆	◆	◆
Benazepril	◆	◆	◆	◆	◆	◆
Bendroflumethiazide	◆	◆	◆	◆	◆	◆
Bosentan	◆	◆	◆	■	■	△
Bumetanide	◆	◆	◆	◆	◆	◆
Candesartan	◆	◆	◆	■	◆	◆
Captopril	◆	◆	◆	◆	◆	◆
Chlorothiazide	◆	◆	◆	◆	◆	◆
Chlortalidone	◆	◆	◆	◆	◆	◆
Cilazapril	◆	◆	◆	◆	◆	◆
Clevidipine	◆	◆	◆	◆	◆	◆
Clonidine	◆	◆	◆	◆	◆	◆
Doxazosin	◆	◆	◆	△	◆	◆
Enalapril	◆	◆	◆	◆	◆	◆
Eplerenone	◆	◆	◆	◆	◆	◆
Epoprostenol	◆	◆	◆	◆	◆	◆
Eprosartan	◆	◆	◆	◆	◆	◆
Fosinopril	◆	◆	◆	◆	◆	◆
Furosemide	◆	◆	◆	◆	◆	◆
Hydralazine	◆	◆	◆	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆	◆	◆	◆
Iloprost	◆	◆	◆	◆	◆	◆
Indapamide	◆	◆	◆	◆	◆	◆
Irbesartan	◆	◆	◆	■	◆	◆
Isradipine	◆	◆	◆	△	◆	△
Ivabradine	◆	◆	◆	◆	◆	◆
Lacidipine	◆	◆	◆	◆	◆	△
Lercanidipine	◆	◆	◆	◆	◆	△
Lisinopril	◆	◆	◆	◆	◆	◆
Losartan	◆	◆	◆	■	◆	◆
Macitentan	◆	◆	◆	◆	◆	◆
Methyldopa	◆	◆	◆	◆	◆	◆
Metolazone	◆	◆	◆	◆	◆	◆
Moxonidine	◆	◆	◆	◆	◆	◆
Olmesartan	◆	◆	◆	■	◆	◆
Perindopril	◆	◆	◆	◆	◆	◆
Prazosin	◆	◆	◆	◆	◆	◆
Quinapril	◆	◆	◆	△	◆	◆
Ramipril	◆	◆	◆	◆	◆	◆
Ranolazine	◆	◆	◆	△	◆	△
Rilmenidine	◆	◆	◆	◆	◆	◆
Riociguat	◆	◆	◆	◆	◆	◆
Sacubitril/valsartan	◆	◆	◆	◆	◆	◆
Selexipag	◆	◆	◆	◆	◆	△
Sildenafil	◆	◆	◆	◆	◆	◆
Sodium nitroprusside	◆	◆	◆	◆	◆	◆
Spironolactone	◆	◆	◆	■	◆	◆
Tadalafil	◆	◆	◆	◆	◆	◆
Telmisartan	◆	◆	◆	■	◆	◆
Torasemide	◆	◆	◆	◆	◆	◆
Trandolapril	◆	◆	◆	◆	◆	◆
Treprostinil	◆	◆	◆	◆	◆	△
Valsartan	◆	◆	◆	◆	◆	◆
Xipamide	◆	◆	◆	◆	◆	◆
Zofenopril	◆	◆	◆	◆	◆	◆

	BZF	ELA	FEN	OCA	SEL	UDCA
Illicit/Recreational						
Alcohol	◆	◆	△	◆	◆	◆
Amphetamine	◆	◆	◆	◆	◆	△
Bromazolam	◆	◆	△	◆	◆	◆
Cannabis	◆	◆	△	◆	◆	◆
Carfentanil	◆	◆	◆	◆	◆	◆
Cocaine	◆	◆	◆	◆	◆	◆
Ecstasy (MDMA)	◆	◆	◆	◆	◆	△
Etizolam	◆	◆	◆	◆	◆	◆
Fentanyl (Recreational)	◆	◆	◆	◆	◆	◆
GHB (Gamma-hydroxybutyrate)	◆	◆	◆	◆	◆	◆
Heroin	◆	◆	◆	◆	◆	◆
Ketamine	◆	◆	◆	◆	◆	◆
LSD (Lysergic acid diethylamide)	◆	◆	◆	◆	◆	△
Mephedrone	◆	◆	◆	◆	◆	△
Methamphetamine	◆	◆	◆	◆	◆	△
Methaqualone	◆	◆	△	◆	◆	◆
Nicotine	◆	◆	◆	◆	◆	◆
Nitazenes	◆	◆	△	△	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆	◆
Phencyclidine (PCP)	◆	◆	◆	◆	◆	△
Xylazine	◆	◆	△	△	◆	◆
Immunosuppressants						
Abatacept	◆	◆	◆	◆	◆	◆
Adalimumab	◆	◆	◆	◆	◆	◆
Alemtuzumab	◆	◆	◆	◆	◆	◆
Anakinra	◆	◆	◆	◆	◆	◆
Apremilast	◆	◆	◆	◆	◆	◆
Azathioprine	◆	◆	◆	◆	◆	◆
Baricitinib	◆	◆	◆	◆	◆	◆
Basiliximab	◆	◆	◆	◆	◆	◆
Belimumab	◆	◆	◆	◆	◆	◆
Brodalumab	◆	◆	◆	◆	◆	◆
Canakinumab	◆	◆	◆	◆	◆	◆
Ciclosporin	■	◆	■	■	■	■
Cladribine (oral)	◆	■	◆	◆	◆	◆
Eculizumab	◆	◆	◆	◆	◆	◆
Etanercept	◆	◆	◆	◆	◆	◆
Fingolimod	◆	◆	◆	◆	◆	◆
Golimumab	◆	◆	◆	◆	◆	◆
Guselkumab	◆	◆	◆	◆	◆	◆
Infliximab	◆	◆	◆	◆	◆	◆
Ixekizumab	◆	◆	◆	◆	◆	◆
Lenalidomide	◆	◆	◆	◆	◆	◆
Mirikizumab	◆	◆	◆	◆	◆	◆
Mycophenolate	◆	◆	△	△	◆	◆
Pirfenidone	◆	◆	◆	◆	◆	◆
Ravulizumab	◆	◆	◆	◆	◆	◆
Risankizumab	◆	◆	◆	◆	◆	◆
Sarilumab	◆	◆	◆	◆	◆	◆
Secukinumab	◆	◆	◆	◆	◆	◆
Siltuximab	◆	◆	◆	◆	◆	◆
Sirolimus	◆	◆	◆	◆	◆	△
Tacrolimus	■	◆	■	■	◆	△
Tildrakizumab	◆	◆	◆	◆	◆	◆
Tocilizumab	◆	◆	◆	◆	◆	◆
Tralokinumab	◆	◆	◆	◆	◆	◆
Ublituximab	◆	◆	◆	◆	◆	◆
Upadacitinib	◆	◆	◆	◆	◆	◆
Ustekinumab	◆	◆	◆	◆	◆	◆
Vedolizumab	◆	◆	◆	◆	◆	◆

For personal use only. Not for distribution. *For personal use only. Not for distribution.* *For personal use only. Not for distribution.* *For personal use only. Not for distribution.*

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; FEN, Fenofibrate; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	FEN	OCA	SEL	UDCA
Lipid Lowering Agents						
Alirocumab	◆	◆	◆	◆	◆	◆
Atorvastatin	■	■	■	■	◆	◆
Bempedoic acid	◆	△	◆	◆	△	△
Evolocumab	◆	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	■	△	◆	◆
Fish oils	◆	◆	◆	◆	◆	◆
Fluvastatin	■	■	■	△	◆	◆
Gemfibrozil	●	△	●	◆	■	◆
Icosapent ethyl	◆	◆	◆	◆	◆	△
Lovastatin	■	■	■	■	◆	◆
Omega-3-6-9 fatty acids	◆	◆	◆	◆	◆	◆
Pitavastatin	■	■	■	■	◆	◆
Pravastatin	■	■	■	◆	◆	◆
Rosuvastatin	■	■	■	◆	◆	◆
Simvastatin	■	■	■	■	◆	◆
Oxytocics						
Ergometrine (ergonovine)	◆	◆	◆	◆	◆	◆
Mifepristone	◆	◆	◆	■	■	◆
Misoprostol	◆	◆	◆	△	◆	◆
Parkinsonism Agents						
Benzatropine (Benztropine)	◆	◆	◆	◆	◆	△
Carbidopa	◆	◆	◆	◆	◆	◆
Levodopa	■	◆	■	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	◆	△
Pramipexole	◆	◆	◆	◆	◆	△
Procyclidine	◆	◆	◆	◆	◆	◆
Rasagiline	△	◆	◆	◆	◆	△
Ropinirole	◆	◆	◆	◆	◆	△
Selegiline	△	◆	◆	◆	◆	◆
Trihexyphenidyl	◆	◆	◆	◆	◆	△
PBC Agents						
Bezafibrate		●	●	◆	◆	◆
Elafibranor	●		●	◆	△	◆
Fenofibrate	●	●		◆	◆	△
Obeticholic acid	◆	◆	◆		◆	◆
Seladelpar	◆	△	◆	◆		◆
Ursodeoxycholic acid	◆	◆	△	◆	◆	
Steroids						
Beclometasone	◆	◆	◆	◆	◆	◆
Betamethasone	■	◆	■	◆	◆	◆
Budesonide	■	◆	■	△	◆	◆
Ciclesonide	◆	◆	◆	◆	◆	◆
Clobetasol (topical)	◆	◆	◆	◆	◆	◆
Clobetasone (topical)	◆	◆	◆	◆	◆	◆
Dexamethasone ≤ 16 mg	■	◆	■	◆	◆	△
Dexamethasone >16 mg	■	◆	■	◆	■	△
Fludrocortisone	■	◆	■	◆	◆	◆
Flunisolide	◆	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆	◆
Methylprednisolone	■	◆	■	◆	◆	◆
Mometasone	◆	◆	◆	◆	◆	◆
Prednicarbate	◆	◆	◆	◆	◆	◆
Prednisone	■	◆	■	◆	◆	◆
Triamcinolone	■	◆	■	◆	◆	◆
Urological Agents						
Alfuzosin	◆	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆
Dutasteride	◆	◆	◆	△	◆	◆
Finasteride	◆	◆	◆	△	◆	◆
Mirabegron	◆	◆	◆	◆	◆	◆
Oxybutynin	◆	◆	◆	◆	◆	△
Propiverine	◆	◆	◆	◆	◆	△
Silodosin	◆	◆	◆	◆	◆	◆
Sodium bicarbonate (oral)	◆	◆	◆	◆	◆	◆
Solifenacin	◆	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	◆	◆
Trospium	◆	◆	◆	◆	◆	◆

	BZF	ELA	FEN	OCA	SEL	UDCA
Other Drugs						
Abaloparatide	◆	◆	◆	◆	◆	◆
Acamprosate	◆	◆	◆	◆	◆	◆
Acetazolamide	◆	◆	◆	◆	◆	◆
Acitretin	◆	◆	◆	△	◆	◆
Activated charcoal	◆	◆	◆	△	△	△
Allopurinol	◆	◆	◆	◆	◆	◆
Atomoxetine	◆	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆	◆
Bamlanivimab/ Etesevimab	◆	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆	◆
Benzonatate	◆	◆	◆	◆	◆	◆
Betahistine	◆	◆	◆	◆	◆	◆
Bimatoprost	◆	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆	△
Brimonidine	◆	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	◆	◆
Brolucizumab	◆	◆	◆	◆	◆	◆
Bromocriptine	◆	◆	◆	◆	◆	◆
Burosumab	◆	◆	◆	◆	◆	◆
Calcitonin	◆	◆	◆	◆	◆	◆
Calcium carbimide	◆	◆	◆	◆	◆	◆
Calcium resonium	◆	◆	◆	◆	◆	◆
Cannabidiol (CBD)	◆	◆	◆	◆	◆	◆
Carbimazole	◆	◆	◆	◆	◆	◆
Carbocisteine	◆	◆	◆	◆	◆	◆
Carisoprodol	◆	◆	■	◆	◆	△
Casirivimab/imdevimab	◆	◆	◆	◆	◆	◆
Cilostazol	◆	◆	◆	◆	◆	◆
Clomifene	◆	◆	◆	◆	◆	◆
Colchicine	■	◆	■	◆	◆	◆
Colestyramine	△	■	△	■	■	■
Conivaptan	◆	◆	◆	◆	◆	◆
COVID-19 vaccines	◆	◆	◆	◆	◆	◆
Cyclobenzaprine	◆	◆	◆	◆	◆	△
Cyproterone acetate	◆	◆	◆	◆	◆	◆
Cytisine	◆	◆	◆	◆	◆	◆
Darbepoetin	◆	◆	◆	◆	◆	◆
Deferiprone	◆	◆	◆	◆	◆	◆
Delgocitinib	◆	◆	◆	◆	◆	◆
Denosumab	◆	◆	◆	◆	◆	◆
Dexamfetamine	◆	◆	◆	◆	◆	△
Dextromethorphan	◆	◆	◆	◆	◆	◆
Disulfiram	◆	◆	◆	■	◆	△
Donepezil	◆	◆	◆	△	◆	◆
Dorzolamide	◆	◆	◆	◆	◆	◆
Dotinurad	◆	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆	◆
Eliglustat	◆	◆	◆	◆	◆	◆
Elinzanetant	◆	◆	◆	△	◆	△
Emicizumab	◆	◆	◆	◆	◆	◆
Epoetin alfa	◆	◆	◆	◆	◆	◆
Etelcalcetide	◆	◆	◆	◆	◆	◆
Fampridine (Dalfampridine)	◆	◆	◆	◆	◆	◆
Faricimab	◆	◆	◆	◆	◆	◆
Febuxostat	◆	◆	◆	△	■	◆
Fezolinetant	◆	◆	◆	■	◆	◆
Filgrastim	◆	◆	◆	◆	◆	◆
Flibanserin	◆	◆	◆	◆	◆	△
Gadopentetate (gadolinium)	◆	◆	◆	◆	◆	◆
Glucose monohydrate (IV)	◆	◆	◆	◆	◆	◆
Glycerol phenylbutyrate	◆	◆	◆	◆	◆	◆
Goserelin acetate	◆	◆	◆	◆	◆	◆
Guanfacine	◆	◆	◆	◆	◆	◆
Idarucizumab	◆	◆	◆	◆	◆	◆
Influenza vaccine	◆	◆	◆	◆	◆	◆
Interferon beta	◆	◆	◆	◆	◆	◆
Isosorbide mononitrate	◆	◆	◆	◆	◆	◆
Isotretinoin	◆	◆	◆	△	◆	△
Lanadelumab	◆	◆	◆	◆	◆	◆
Lanreotide	◆	◆	◆	◆	◆	◆
Lisdexamfetamine	◆	◆	◆	◆	◆	◆
Lebrikizumab	◆	◆	◆	◆	◆	◆
Lecanemab	◆	◆	◆	◆	◆	◆
Leuprorelin acetate	◆	◆	◆	◆	◆	◆
Levothyroxine	◆	◆	◆	◆	◆	◆
Lisdexamfetamine	◆	◆	◆	◆	◆	◆
Lofexidine	◆	◆	◆	◆	◆	◆
Lumacaftor/Ivacaftor	◆	■	◆	◆	■	◆
Magnesium	◆	◆	◆	◆	◆	◆
Maralixibat	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	△

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; FEN, Fenofibrate; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	FEN	OCA	SEL	UDCA
Other Drugs Continued						
Mepolizumab	◆	◆	◆	◆	◆	◆
Methimazole (Thiamazole)	◆	◆	◆	◆	◆	◆
Methylphenidate	◆	◆	◆	◆	◆	◆
Midodrine	◆	◆	◆	◆	◆	◆
Minoxidil	◆	◆	◆	◆	◆	◆
Modafinil	◆	◆	◆	◆	■	◆
Naftidrofuryl	◆	◆	◆	◆	◆	◆
Nalmefene	◆	△	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆
Nemolizumab	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆	◆
Nusinersen	◆	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆	◆
Orforglipron	◆	◆	◆	◆	◆	△
Orlistat	◆	◆	◆	△	△	△
Pancreatic enzymes	◆	◆	◆	◆	◆	◆
Penicillamine	■	◆	■	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆	◆
Phentermine	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆
Piracetam	◆	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆	◆
Propylthiouracil	◆	◆	◆	◆	◆	◆
Protamine sulphate	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	◆
Pyridostigmine	◆	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	◆	◆	◆
Resmetirom	◆	◆	◆	△	△	△
Romosozumab	◆	◆	◆	◆	◆	◆
Rozanolixizumab	◆	◆	◆	◆	◆	◆
Selegiline	◆	◆	◆	◆	◆	◆
Sevelamer	◆	△	◆	△	△	△
Sodium zirconium cyclosilicate	◆	◆	◆	◆	◆	◆
Sotatercept	◆	◆	◆	◆	◆	◆
Strontium ranelate	◆	◆	◆	◆	◆	◆
Tetrabenazine	◆	◆	◆	△	◆	△
Thalidomide	◆	◆	◆	◆	◆	◆
Triptorelin	◆	◆	◆	◆	◆	◆
Tranexamic acid	◆	◆	◆	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆

Using a saved or printed version? Click or scan to check for updates.

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
△	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.